Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2023 | How do the approved NMOSD therapies work?

Bruce Cree, MD, PhD, MAS, University of California San Francisco, San Francisco, CA, explores the game-changing treatments recently introduced for patients with neuromyelitis optica spectrum disorder (NMOSD). The three approved therapies – eculizumab, inebilizumab, and satralizumab- target different aspects of NMOSD immunopathogenesis. This marks a remarkable shift from having no proven therapies to highly effective options, revolutionizing NMOSD management. This interview took place at the European Academy of Neurology (EAN) 2023 Congress in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Bruce Cree reports the following disclosures: I have received personal compensation for consulting from Alexion, Atara, Autobahn, Avotres, Biogen, Boston Pharma, EMD Serono, Gossamer Bio, Hexal/Sandoz, Horizon, Immunic AG, Neuron23, Novartis, Sanofi, Siemens and TG Therapeutics and UCSF has received research support from Genentech.